|
AM8641b-ev
|
Abcepta, Inc.
|
TLR2 [1070CT4.2.3.2], Mouse Monoclonal Antibody
|
Human
|
WB
|
|
|
AM8641b
|
Abcepta, Inc.
|
TLR2 [1070CT4.2.3.2], Mouse Monoclonal Antibody
|
Human
|
WB
|
|
|
TE482a
|
TissueArray.com (US Biomax)
|
Multiple testis tumor and testis tissue array, 24 cases/48 cores
|
Human
|
IHC
|
|
|
ATGP1490-250ug
|
NKMax Bio (ATGen)
|
Antigen 85A [43-338 a.a.], Recombinant Protein
|
Mycobacterium tuberculosis
|
SDS-PAGE
|
|
|
ATGP1490-50ug
|
NKMax Bio (ATGen)
|
Antigen 85A [43-338 a.a.], Recombinant Protein
|
Mycobacterium tuberculosis
|
SDS-PAGE
|
|
|
ATGP1480-250ug
|
NKMax Bio (ATGen)
|
ESAT6 [1-95 a.a.], Recombinant Protein
|
Mycobacterium tuberculosis
|
SDS-PAGE
|
|
|
ATGP1480-50ug
|
NKMax Bio (ATGen)
|
ESAT6 [1-95 a.a.], Recombinant Protein
|
Mycobacterium tuberculosis
|
SDS-PAGE
|
|
|
ATGP3807-250ug
|
NKMax Bio (ATGen)
|
IFN-gamma R1 [18-245 a.a.], Recombinant Protein
|
Human
|
SDS-PAGE
|
|
|
ATGP3807-50ug
|
NKMax Bio (ATGen)
|
IFN-gamma R1 [18-245 a.a.], Recombinant Protein
|
Human
|
SDS-PAGE
|
|
|
GTX13960
|
GeneTex International Corporation
|
Mycobacterium tuberculosis ESAT6, Rabbit Polyclonal Antibody
|
Mycobacterium tuberculosis
|
WB
|
|
|
HY-101867-10mg
|
MedChemexpress LLC
|
AU1235 [CAS 1338780-86-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101867-100mg
|
MedChemexpress LLC
|
AU1235 [CAS 1338780-86-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101867-2mg
|
MedChemexpress LLC
|
AU1235 [CAS 1338780-86-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101867-25mg
|
MedChemexpress LLC
|
AU1235 [CAS 1338780-86-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101867-5mg
|
MedChemexpress LLC
|
AU1235 [CAS 1338780-86-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101867-50mg
|
MedChemexpress LLC
|
AU1235 [CAS 1338780-86-1]
|
|
Cancer-programmed cell death
|
|
|
HY-117145-5mg
|
MedChemexpress LLC
|
Thiophene-2 [CAS 420089-51-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-12904-10mg
|
MedChemexpress LLC
|
TCA1 [CAS 864941-32-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-12904-100mg
|
MedChemexpress LLC
|
TCA1 [CAS 864941-32-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-12904-25mg
|
MedChemexpress LLC
|
TCA1 [CAS 864941-32-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-12904-5mg
|
MedChemexpress LLC
|
TCA1 [CAS 864941-32-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-12904-50mg
|
MedChemexpress LLC
|
TCA1 [CAS 864941-32-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13579-10mg
|
MedChemexpress LLC
|
BTZ043 [CAS 1161233-85-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13579-100mg
|
MedChemexpress LLC
|
BTZ043 [CAS 1161233-85-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13579-5mg
|
MedChemexpress LLC
|
BTZ043 [CAS 1161233-85-7]
|
|
Cancer-programmed cell death
|
|
